SCHEMBL4628481

SCHEMBL4628481

COc1cc(C(=O)NC(=N)NCCCCc2ccccc2)cc(OC)c1OC

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.64
LMNA P02545 2/20 0.64
HTT P42858 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
SCN5A Q14524 1/20 0.62
SCN2A Q99250 1/20 0.62
KMT2A Q03164 5/20 0.56
MEN1 O00255 2/20 0.56
ALDH1A1 P00352 2/20 0.55
POLB P06746 2/20 0.53
MAPK1 P28482 1/20 0.53
KDM4E B2RXH2 1/20 0.52
BRD4 O60885 1/20 0.51
HPGD P15428 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629411 0.92 LMNA (0.65) SMN1; SMN2LMNAHTTTDP1L3MBTL1
SCHEMBL4628718 0.83 ALDH1A1 (0.62) LMNAHTTTDP1L3MBTL1SCN5A
SCHEMBL4628372 0.82 ALDH1A1 (0.61) LMNAHTTTDP1L3MBTL1SCN5A
SCHEMBL4629466 0.82 NPC1 (0.65) SMN1; SMN2LMNAL3MBTL1SCN5ASCN2A
SCHEMBL4629427 0.79 SCN5A (0.70) SMN1; SMN2LMNASCN5ASCN2AKMT2A
SCHEMBL4629469 0.78 SMN1; SMN2 (0.52) SMN1; SMN2LMNAHTTTDP1L3MBTL1
SCHEMBL4627587 0.78 SCN5A (0.69) SMN1; SMN2LMNAL3MBTL1SCN5ASCN2A
SCHEMBL14810218 0.77 SMO (0.65) SMN1; SMN2LMNAHTTTDP1L3MBTL1
SCHEMBL4628492 0.77 SCN5A (1.00) SMN1; SMN2LMNAHTTTDP1L3MBTL1
SCHEMBL4628488 0.76 MAPT (0.65) SMN1; SMN2LMNAHTTL3MBTL1SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SMN1; SMN2 53/4885LMNA 1283/4885HTT 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.